HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI)

Investment analysts at HC Wainwright started coverage on shares of Palisade Bio (NASDAQ:PALI) in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 246.53% from the company’s previous close.

Several other equities analysts also recently commented on the stock. Piper Sandler started coverage on shares of Palisade Bio in a research note on Monday, December 29th. They issued an “overweight” rating and a $25.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Finally, Stifel Nicolaus assumed coverage on Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Palisade Bio Price Performance

Shares of NASDAQ PALI opened at $2.02 on Thursday. The firm has a market cap of $335.08 million, a price-to-earnings ratio of -0.95 and a beta of 1.53. The stock’s fifty day moving average price is $1.77 and its two-hundred day moving average price is $1.73. Palisade Bio has a one year low of $0.53 and a one year high of $2.64.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new stake in Palisade Bio during the fourth quarter worth $28,318,000. Commodore Capital LP bought a new position in shares of Palisade Bio in the 4th quarter valued at $26,896,000. Janus Henderson Group PLC acquired a new position in shares of Palisade Bio during the 4th quarter worth $24,822,000. RA Capital Management L.P. acquired a new position in shares of Palisade Bio during the 4th quarter worth $16,742,000. Finally, Eversept Partners LP bought a new stake in shares of Palisade Bio during the 4th quarter worth $12,670,000. 11.79% of the stock is owned by institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.